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A Corrigendum on
Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth
and Alters Tumor Heterogeneity
By La Manna F, De Menna M, Patel N, Karkampouna S, De Filippo MR, Klima I, Kloen P, Beimers L,
Thalmann GN, Pelger RCM, Jacinto E and Kruithof-de Julio M (2020). Front. Oncol. 10:1012.
doi: 10.3389/fonc.2020.01012
An author name was incorrectly spelled as “Maria De Filippo”. The correct spelling is “Maria
Rosaria De Filippo”.
In the published article, there was also an error in affiliation 1. Instead of “Department of
BioMedical Research, University of Bern, Bern, Switzerland”, it should be “Department for
BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland”.
There was also an error in the text. The concentration and administration schedule of Rapalink-1
reported for the in vivo experiment was not correct. The error appeared both in the “Materials and
Methods” and in the “Results” sections, where it is incorrectly reported as “1.5 mg/g [ … ] every 5
days” and “1.5 mg/g/6 days”, respectively. Figure 5C in the original article reported the correct
administration schedule.
A correction has been made to the “Materials and Methods” section, “Animals Maintenance and
in vivo Experiment” sub-section:
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La Manna et al. Corrigendum: Dual-mTOR Inhibitor Targets Prostate Cancer
Fronti“Group 1 received 3.5 ml/g of vehicle (20% DMSO,
40% PEG-300 and 40% PBS) i.p. once a week while
group 2 received Rapalink-1 (1.5 mg/Kg) resuspended
in vehicle, i.p. every 5-7 days.”A correction of the same error has been made to the “Results”
section, “Treatment of LAPC9 in vivo With Rapalink-1 Delays
Tumor Growth” sub-section, paragraph 2:“We then assessed the effect of Rapalink-1 (1.5 mg/Kg/
5-7 days) in vivo on LAPC9 PDX model, comparing
the treatment to vehicle only, a schematic of treatment
schedule is reported (Figure 5C).”ers in Oncology | www.frontiersin.org 2The authors apologize for these errors and state that this does
not change the scientific conclusions of the article in any way.
The original article has been updated.Copyright © 2021 La Manna, De Menna, Patel, Karkampouna, De Filippo, Klima,
Kloen, Beimers, Thalmann, Pelger, Jacinto and Kruithof-de Julio. This is an
open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.February 2021 | Volume 11 | Article 650623
